novo nordisk semaglutide clinical trials 2021Q3 Novo Nordisk shares slide after
Description
AAV Mediated Exendin-4 Gene Transfer to Salivary Glands to Protect Subjects from Diabetes or Obesity
Experts say supporting gut and heart health, preserving muscle, and protecting bone are essential for long-term success
No patients receiving GLP-1 RAs were excluded due to loss of follow-up, while 8 patients (0.2%) who did not receive GLP-1 RAs were excluded for this reason (Supplemental Table 3)
Procedures such as gastric bypass or sleeve gastrectomy typically result in 25-30% total body weight loss and often lead to diabetes remission
Their motivations can vary, driven by concerns such as health (50%), appearance (35%) or mood (15%).17 As a result, they may not perceive their need as strictly medical and so may be put off by products with overtly medical aesthetics
Acknowledgements We thank all the participants, investigators, and trial-site staff who were involved in the conduct of these trials
